IDWeek 2012

A pooled analysis of four randomized, active-controlled Phase 3 clinical trials presented at IDWeek 2012 has shown that moxifloxacin is an effective and safe option for secondary peritonitis.

The pharmacokinetics across combinations of concomitant telaprevir and efavirenz or atazanavir/ritonavir-based regiments in hepatitis C (HCV)/HIV co-infected patients were comparable and consistent with those observed historically in HCV mono-infected patients, according to Varun Garg, PhD, from Vertex Pharmaceuticals, Inc., Cambridge, MA, at IDWeek 2012.

Response to anti-tuberculous treatment in patients with chronic kidney disease (CKD) was effective, although not as robust as seen in patients with normal glomerular filtration rate (GFR), noted Teny Mathew John, MD, DNB, from Hamad General Hospital, Doha, Qatar, India, at IDWeek 2012.

Results from a Phase 2 study reported on at IDWeek 2012 showed that the 5555 formulation of tetravalent dengue vaccine elicits the highest serpositivity rates and balanced response against all four serotypes with a satisfactory safety profile.

At IDWeek 2012, study researchers presented data showing that MenACWY-CRM, a quadrivalent meningococcal conjugate vaccine, has been shown to be highly immunogenic and well tolerated across age groups.

Efavirenz-, atazanavir + ritonavir-, and raltegravir-containing regimens are compatible for use with direct acting antivirals, stated Sonia Vibhakar, PharmD, from The Ruth M. Rothstein CORE Center, Chicago, IL, and colleagues, at IDWeek 2012.

Pranita Tamma, MD, MHS, from The Johns Hopkins Medical Institution, Baltimore, MD, reported on colistin use in children at IDWeek 2012.

School-aged children diagnosed with community-acquired pneumonia (CAP) in the outpatient setting are less likely to fail treatment when treated with macrolide monotherapy, study investigators reported at IDWeek 2012.

Use of intranasal mupirocin as a strategy to prevent methicillin-resistant Staphylococcus aureus (MRSA) in the neonatal intensive care unit (NICU) is limited by a 50% recolonization rate in some high-risk neonates, reported Sara M. Wittig, MPH, CIC, from Johns Hopkins Hospital, Baltimore, MD, at IDWeek 2012.

At IDWeek 2012, study investigators reported that the combination of voriconazole and caspofungin was associated with an improved response compared to caspofungin alone as primary therapy of invasive aspergillosis in patients with hematologic malignancy.